Piotr Milkiewicz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3265581/publications.pdf

Version: 2024-02-01

166 papers 5,803 citations

39 h-index 91884 69 g-index

171 all docs

171 docs citations

171 times ranked

7753 citing authors

#	Article	IF	Citations
1	Impact on followâ€up strategies in patients with primary sclerosing cholangitis. Liver International, 2023, 43, 127-138.	3.9	15
2	Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship. European Journal of Clinical Investigation, 2022, 52, e13622.	3.4	63
3	Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut, 2022, 71, 1141-1151.	12.1	32
4	MARC1 polymorphism is associated with decreased markers of liver injury and enhanced antioxidant capacity in patients with AIH. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0
5	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	3.7	21
6	DHEA Protects Human Cholangiocytes and Hepatocytes against Apoptosis and Oxidative Stress. Cells, 2022, 11, 1038.	4.1	10
7	Liquid chromatography coupled to tandem mass spectrometry methods for the selective and sensitive determination of 24Sâ€hydroxycholesterol, its sulfate, and/or glucuronide conjugates in plasma. Journal of Mass Spectrometry, 2022, 57, e4827.	1.6	2
8	Modulation of Mismatch Repair and the SOCS1/p53 Axis by microRNA-155 in the Colon of Patients with Primary Sclerosing Cholangitis. International Journal of Molecular Sciences, 2022, 23, 4905.	4.1	2
9	Controlled Attenuation Parameter in Nonalcoholic Fatty Liver Disease: The Thresholds Do Matter. Clinical Gastroenterology and Hepatology, 2021, 19, 1507-1508.	4.4	4
10	Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis. Liver International, 2021, 41, 348-356.	3.9	16
11	Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference. Journal of Clinical Medicine, 2021, 10, 1507.	2.4	9
12	Chronic Fatigue Persists in a Significant Proportion of Female Patients After Transplantation for Primary Sclerosing Cholangitis. Liver Transplantation, 2021, 27, 1032-1040.	2.4	5
13	Role of miR-506 in ulcerative colitis associated with primary sclerosing cholangitis. Scientific Reports, 2021, 11, 10134.	3.3	8
14	Splenic tumor in a patient after liver transplantation. Gastroenterology, 2021, , .	1.3	0
15	Genetic aspects of adult and pediatric autoimmune hepatitis: A concise review. European Journal of Medical Genetics, 2021, 64, 104214.	1.3	10
16	Dehydroepiandrosterone sulfate indicates decreased sulfation capacity and impaired quality of life in Primary Sclerosing Cholangitis. Polish Archives of Internal Medicine, 2021, 131, 790-796.	0.4	2
17	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. JHEP Reports, 2021, 3, 100276.	4.9	5
18	Epithelia-Sensory Neuron Cross Talk Underlies Cholestatic Itch Induced by Lysophosphatidylcholine. Gastroenterology, 2021, 161, 301-317.e16.	1.3	57

#	Article	IF	CITATIONS
19	Outcome of pregnancy in patients with primary sclerosing cholangitis. Digestive and Liver Disease, 2021, , .	0.9	5
20	Antiâ∈glycoprotein 2 (antiâ∈CP2) IgA and antiâ∈neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3â∈ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 302-313.	3.7	19
21	p-STAT3 is a PDC-E2 interacting partner in human cholangiocytes and hepatocytes with potential pathobiological implications. Scientific Reports, 2021, 11, 21649.	3.3	2
22	Health-related quality of life in autoimmune hepatitis. World Journal of Hepatology, 2021, 13, 1642-1652.	2.0	6
23	MARC1 p.A165T variant is associated with decreased markers of liver injury and enhanced antioxidant capacity in autoimmune hepatitis. Scientific Reports, 2021, 11, 24407.	3.3	10
24	Editorial: serologic antibodies in primary sclerosing cholangitisâ€"a tellâ€tale sign of compromised gutâ€liver immunity? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 352-353.	3.7	0
25	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology, 2020, 72, 1253-1266.	7.3	42
26	Vitamin-D Receptor-Gene Polymorphisms Affect Quality of Life in Patients with Autoimmune Liver Diseases. Nutrients, 2020, 12, 2244.	4.1	10
27	Melatonin Protects Cholangiocytes from Oxidative Stress-Induced Proapoptotic and Proinflammatory Stimuli via miR-132 and miR-34. International Journal of Molecular Sciences, 2020, 21, 9667.	4.1	14
28	COVIDâ€19: Focus on the lungs but do not forget the gastrointestinal tract. European Journal of Clinical Investigation, 2020, 50, e13276.	3.4	45
29	The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia. Autoimmunity Highlights, 2020, 11 , 6 .	3.9	6
30	Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation. Liver International, 2020, 40, 3103-3116.	3.9	20
31	Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in Management. Hepatology Communications, 2020, 4, 399-408.	4.3	6
32	TGF-Î ² 2 silencing to target biliary-derived liver diseases. Gut, 2020, 69, 1677-1690.	12.1	31
33	Enhanced expression of miR-21 and miR-150 is a feature of anti-mitochondrial antibody-negative primary biliary cholangitis. Molecular Medicine, 2020, 26, 8.	4.4	9
34	Oncomir MicroRNA-346 Is Upregulated in Colons of Patients With Primary Sclerosing Cholangitis. Clinical and Translational Gastroenterology, 2020, 11, e00112.	2.5	8
35	Modifiable Factors and Genetic Predisposition Associated with Gallbladder Cancer. A Concise Review. Journal of Gastrointestinal and Liver Diseases, 2020, 24, 339-348.	0.9	8
36	Genetic Risk Factors for Autoimmune Thyroid Disease might Affect the Susceptibility to and Modulate the Progression of Primary Biliary Cholangitis. Journal of Gastrointestinal and Liver Diseases, 2020, 26, 245-252.	0.9	11

3

#	Article	IF	CITATIONS
37	Plasmapheresis improves chronic fatigue in patients with primary biliary cholangitis. Polish Archives of Internal Medicine, 2020, 131, 205-207.	0.4	4
38	Etiology of Liver Disease and Cardiovascular Abnormalities in Patients on a Liver Transplantation Waiting List. Annals of Transplantation, 2019, 24, 162-167.	0.9	0
39	Difficult iatrogenic bile duct injuries following different types of upper abdominal surgery: report of three cases and review of literature. BMC Surgery, 2019, 19, 162.	1.3	5
40	Acute liver injury, acute liver failure and acute on chronic liver failure: A clinical spectrum of poisoning due to Gyromitra esculenta. Annals of Hepatology, 2019, 18, 514-516.	1.5	12
41	The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study. Frontiers in Immunology, 2019, 10, 662.	4.8	21
42	Depression: An Overlooked Villain in Autoimmune Hepatitis?. Hepatology, 2019, 70, 2232-2233.	7.3	9
43	The Association between SOCS1â^1656G>A Polymorphism, Insulin Resistance and Obesity in Nonalcoholic Fatty Liver Disease (NAFLD) Patients. Journal of Clinical Medicine, 2019, 8, 1912.	2.4	8
44	Fineâ€Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease. Hepatology, 2019, 69, 699-716.	7.3	33
45	Autoimmune hepatitis exerts a profound, negative effect on healthâ€related quality of life: A prospective, singleâ€centre study. Liver International, 2019, 39, 215-221.	3.9	34
46	Agingâ€Related Expression of Twinfilinâ€1 Regulates Cholangiocyte Biological Response to Injury. Hepatology, 2019, 70, 883-898.	7.3	9
47	The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis. Hepatology, 2019, 69, 1632-1647.	7. 3	42
48	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology, 2019, 70, 547-562.	7.3	112
49	Long-Term Health-Related Quality of Life in Living Liver Donors. Annals of Transplantation, 2019, 24, 45-51.	0.9	23
50	Effect of S-Adenosyl-L-Methionine on Liver Biochemistry and Quality of Life in Patients with Primary Biliary Cholangitis Treated with Ursodeoxycholic Acid. A Prospective, Open Label Pilot Study. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 273-279.	0.9	26
51	Depression in autoimmune hepatitis: a need for detailed psychiatric assessment. Polish Archives of Internal Medicine, 2019, 129, 645-647.	0.4	4
52	Reply to: "Diagnostic and prognostic role of circulating microparticles in hepatocellular carcinoma― Journal of Hepatology, 2018, 68, 203-204.	3.7	0
53	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	12.1	42
54	Gut Permeability Might be Improved by Dietary Fiber in Individuals with Nonalcoholic Fatty Liver Disease (NAFLD) Undergoing Weight Reduction. Nutrients, 2018, 10, 1793.	4.1	56

#	Article	IF	CITATIONS
55	Effects of liver transplantation on healthâ€related quality of life in patients with primary biliary cholangitis. Clinical Transplantation, 2018, 32, e13434.	1.6	9
56	PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC. PLoS ONE, 2018, 13, e0202942.	2.5	7
57	N-3 Polyunsaturated Fatty Acids Stimulate Bile Acid Detoxification in Human Cell Models. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-12.	1.9	10
58	Successful DAA-Based Treatment of HCV-Related Fibrosing Cholestatic Hepatitis After Liver Transplantation Due to a Fulminant Liver Failure. American Journal of Gastroenterology, 2018, 113, 1062-1063.	0.4	2
59	Urinary Elimination of Bile Acid Glucuronides under Severe Cholestatic Situations: Contribution of Hepatic and Renal Glucuronidation Reactions. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-12.	1.9	12
60	Pretransplant QT Interval: The Relationship with Severity and Etiology of Liver Disease and Prognostic Value After Liver Transplantation. Annals of Transplantation, 2018, 23, 622-630.	0.9	14
61	The Pre-Transplant Profile of Cardiovascular Risk Factors and Its Impact on Long-Term Mortality After Liver Transplantation. Annals of Transplantation, 2018, 23, 591-597.	0.9	14
62	Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 282-292.	3.7	123
63	Enhanced liver fibrosis test predicts transplantâ€free survival in primary sclerosing cholangitis, a multiâ€centre study. Liver International, 2017, 37, 1554-1561.	3.9	54
64	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	1.3	355
65	Good outcome following liver transplantation using pericardial-peritoneum window for hepato-atrial anastomosis to overcome advanced hepatic alveolar echinococcosis and secondary Budd-Chiari Syndrome - a case report. BMC Surgery, 2017, 17, 5.	1.3	6
66	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2017, 66, 1125-1143.	7.3	218
67	Protection against oxidative stress mediated by the Nrf2/Keap1 axis is impaired in Primary Biliary Cholangitis. Scientific Reports, 2017, 7, 44769.	3.3	67
68	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 2017, 49, 269-273.	21.4	230
69	Does transient elastography correlate with liver fibrosis in patients with PSC? Laennec score-based analysis of explanted livers. Scandinavian Journal of Gastroenterology, 2017, 52, 1407-1412.	1.5	14
70	A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients. BMC Medical Genomics, 2017, 10, 2.	1.5	18
71	Plasmapheresis exerts a longâ€lasting antipruritic effect in severe cholestatic itch. Liver International, 2017, 37, 743-747.	3.9	20
72	Polymorphisms of IL12RB2 May Affect the Natural History of Primary Biliary Cholangitis: A Single Centre Study. Journal of Immunology Research, 2017, 2017, 1-5.	2.2	5

#	Article	IF	CITATIONS
73	Apal polymorphism of vitamin D receptor affects health-related quality of life in patients with primary sclerosing cholangitis. PLoS ONE, 2017, 12, e0176264.	2.5	11
74	Decreased Expression of Vitamin D Receptor Affects an Immune Response in Primary Biliary Cholangitis via the VDR-miRNA155-SOCS1 Pathway. International Journal of Molecular Sciences, 2017, 18, 289.	4.1	48
7 5	Orthotopic liver transplantation (OLTx) in non-cirrhotic portal hypertension secondary to ADAMTS13 deficiency. Przeglad Gastroenterologiczny, 2016, 1, 56-58.	0.7	2
76	Nutritional Strategies for the Individualized Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) Based on the Nutrient-Induced Insulin Output Ratio (NIOR). International Journal of Molecular Sciences, 2016, 17, 1192.	4.1	23
77	Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis. Scientific Reports, 2016, 6, 39573.	3.3	24
78	Selective and sensitive quantification of the cytochrome P450 3A4 protein in human liver homogenates through multiple reaction monitoring mass spectrometry. Proteomics, 2016, 16, 2827-2837.	2.2	8
79	Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases. Scientific Reports, 2016, 6, 30847.	3.3	48
80	Assessment of health related quality of life in polish patients with primary biliary cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 471-479.	1.5	35
81	Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease. Liver Transplantation, 2016, 22, 34-41.	2.4	60
82	Reduction of Caloric Intake Might Override the Prosteatotic Effects of the <i>PNPLA3</i> p.I148M and <i>TM6SF2</i> p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study. Digestion, 2016, 93, 139-148.	2.3	27
83	Factors Affecting Exercise Test Performance in Patients After Liver Transplantation. Hepatitis Monthly, 2016, 16, e34356.	0.2	6
84	Heterozygous Inactivation of the Nuclear Receptor PXR/NR112 in a Patient With Anabolic Steroid-Induced Intrahepatic Cholestasis. Hepatitis Monthly, 2016, 16, e35953.	0.2	5
85	Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. Scientific Reports, 2015, 5, 13462.	3.3	78
86	Variant adiponutrin confers genetic protection against cholestatic itch. Scientific Reports, 2015, 4, 6374.	3.3	6
87	Evolution Of The Results Of 1500 Liver Transplantations Performed In The Department Of General, Transplant And Liver Surgery Medical University Of Warsaw. Polski Przeglad Chirurgiczny, 2015, 87, 221-30.	0.4	7
88	Leisure time physical activity and health-related behaviours after liver transplantation: a prospective, single-centre study. Przeglad Gastroenterologiczny, 2015, 2, 100-104.	0.7	7
89	Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXR. Journal of Immunology Research, 2015, 2015, 1-8.	2.2	16
90	Antiâ€kelchâ€like 12 and antiâ€hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver International, 2015, 35, 642-651.	3.9	66

#	Article	IF	CITATIONS
91	Prospective evaluation of <scp>PBC</scp> â€specific healthâ€related quality of life questionnaires in patients with primary sclerosing cholangitis. Liver International, 2015, 35, 1764-1771.	3.9	31
92	Ferroportin-related haemochromatosis associated with novel Y64H mutation of the SCL40A1 gene. Przeglad Gastroenterologiczny, 2014, 5, 307-309.	0.7	4
93	PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC). PLoS ONE, 2014, 9, e112877.	2.5	57
94	Factors Affecting Health-Related Quality of Life and Physical Activity after Liver Transplantation for Autoimmune and Nonautoimmune Liver Diseases: A Prospective, Single Centre Study. Journal of Immunology Research, 2014, 2014, 1-9.	2,2	23
95	Ursodeoxycholic Acid Influences the Expression of Amml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"> <mml:mtext>p</mml:mtext> <mml:msup><mml:mrow><mml:mtext>27</mml:mtext></mml:mrow><n biliary="" cirrhosis.="" foxo1="" immunology="" in="" journal="" non-cirrhotic="" not="" of="" patients="" primary="" research,<="" td="" with=""><td>าmbเชrow</td><td>><ធាml:mtex</td></n></mml:msup>	า mbเช row	><ធាml:mtex
96	Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology, 2014, 60, 931-940.	7.3	99
97	Relationship Between Pretransplantation Liver Status and Health-Related Quality of Life After Grafting: A Single-Center Prospective Study. Transplantation Proceedings, 2014, 46, 2770-2773.	0.6	3
98	Mini-Mental State Examination in patients with hepatic encephalopathy and liver cirrhosis: a prospective, quantified electroencephalography study. BMC Gastroenterology, 2013, 13, 107.	2.0	21
99	Normalization of the psychometric hepatic encephalopathy score in Polish population. A prospective, quantified electroencephalography study. Liver International, 2013, 33, 1332-1340.	3.9	20
100	Activation of FoxO3a/Bim axis in patients with Primary Biliary Cirrhosis. Liver International, 2013, 33, 231-238.	3.9	21
101	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013, 45, 670-675.	21.4	339
102	In patients with liver cirrhosis, proinflammatory interleukins correlate with health-related quality of life irrespective of minimal hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2013, 25, 1402-1407.	1.6	14
103	TRAF1-C5Affects Quality of Life in Patients with Primary Biliary Cirrhosis. Clinical and Developmental Immunology, 2013, 2013, 1-7.	3.3	9
104	Serum natremia affects health-related quality of life in patients with liver cirrhosis: a prospective, single centre study. Annals of Hepatology, 2013, 12, 448-455.	1.5	6
105	Role of Glucuronidation for Hepatic Detoxification and Urinary Elimination of Toxic Bile Acids during Biliary Obstruction. PLoS ONE, 2013, 8, e80994.	2.5	35
106	Endoscopic submucosal dissection for the treatment of neoplastic lesions in the gastrointestinal tract. World Journal of Gastroenterology, 2013, 19, 1953.	3.3	31
107	Isolated right posterior bile duct injury following cholecystectomy: Report of two cases. World Journal of Gastroenterology, 2013, 19, 6118.	3.3	16
108	Serum natremia affects health-related quality of life in patients with liver cirrhosis: a prospective, single centre study. Annals of Hepatology, 2013, 12, 448-55.	1.5	2

#	Article	IF	CITATIONS
109	Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at $13q14$, multiple independent associations at four established risk loci and epistasis between $1p31$ and $7q32$ risk variants. Human Molecular Genetics, 2012 , 21 , 5209 - 5221 .	2.9	139
110	The Efficacy and Safety of Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis for Treatment of Pain in Patients with Pancreatic Cancer. Gastroenterology Research and Practice, 2012, 2012, 1-5.	1.5	33
111	Vitamin D Receptor Polymorphisms Predispose to Primary Biliary Cirrhosis and Severity of the Disease in Polish Population. Gastroenterology Research and Practice, 2012, 2012, 1-8.	1.5	24
112	TRAF1Gene Polymorphism Correlates with the Titre of Gp210 Antibody in Patients with Primary Biliary Cirrhosis. Clinical and Developmental Immunology, 2012, 2012, 1-7.	3.3	7
113	Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22. Autoimmunity Highlights, 2012, 3, 1-9.	3.9	8
114	Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies. Autoimmunity Highlights, 2012, 3, 105-112.	3.9	7
115	Lipidic last breath of life in patients with alcoholic liver disease. Prostaglandins and Other Lipid Mediators, 2012, 99, 51-56.	1.9	34
116	Angiogenesis within the duodenum of patients with cirrhosis is modulated by mechanosensitive <scp>K</scp> ruppelâ€like factor 2 and micro <scp>RNA</scp> â€126. Liver International, 2012, 32, 1222-1232.	3.9	14
117	Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: A pilot study. Digestive and Liver Disease, 2012, 44, 303-310.	0.9	118
118	Endoscopic submucosal dissection for treatment of gastric subepithelial tumors (with video). Gastrointestinal Endoscopy, 2012, 75, 276-286.	1.0	145
119	The pathogenesis of chronic fatigue in primary biliary cirrhosis. Przeglad Gastroenterologiczny, 2012, 4, 192-196.	0.7	O
120	Liver transplantation in chronic cholestatic conditions. Frontiers in Bioscience - Landmark, 2012, 17, 959.	3.0	14
121	Direct pressure measurement in the hepatic artery during liver transplantation: can it prevent the "steal―syndrome?. Clinical Transplantation, 2012, 26, 223-228.	1.6	6
122	Esophageal duplication cysts: Endosonographic findings in asymptomatic patients. World Journal of Gastroenterology, 2012, 18, 1270.	3.3	30
123	Pancreatoduodenectomy with a Modified Duct-To-Mucosa Pancreaticojejunostomy: An Analysis of 101 Consecutive Patients. Hepato-Gastroenterology, 2012, 59, 1626-30.	0.5	2
124	Factors associated with advanced liver fibrosis in patients with non-alcoholic liver disease. Przeglad Gastroenterologiczny, 2011, 4, 234-242.	0.7	0
125	Profiling Circulating and Urinary Bile Acids in Patients with Biliary Obstruction before and after Biliary Stenting. PLoS ONE, 2011, 6, e22094.	2.5	87
126	Minimal hepatic encephalopathy does not impair health-related quality of life in patients with cirrhosis: a prospective study. Liver International, 2011, 31, 980-984.	3.9	30

#	Article	IF	CITATIONS
127	Cholestasis induced by Chinese herbal remedy Xia-Ku-Hua-Tan-Pian. Liver International, 2011, 31, 746-747.	3.9	4
128	Surgical management and outcome of bile duct injuries following cholecystectomy: a single-center experience. Langenbeck's Archives of Surgery, 2011, 396, 699-707.	1.9	24
129	Primary Sclerosing Cholangitis. Recent Results in Cancer Research, 2011, 185, 117-133.	1.8	10
130	Nodular regenerative hyperplasia: Evolving concepts on underdiagnosed cause of portal hypertension. World Journal of Gastroenterology, 2011, 17, 1400.	3.3	146
131	Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterology, 2010, 10, 67.	2.0	51
132	Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 655-657.	21.4	205
133	Critical flicker frequency fails to disclose brain dysfunction in patients with primary biliary cirrhosis. Digestive and Liver Disease, 2010, 42, 818-821.	0.9	5
134	PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. Journal of Autoimmunity, 2010, 35, 436-442.	6.5	123
135	Prevalence of â€~deep' rectal varices in patients with cirrhosis: an EUSâ€based study. Liver International, 2009, 29, 1202-1205.	3.9	19
136	Author's reply: PBC-specific autoantibodies in patients with systemic sclerosis. Digestive and Liver Disease, 2009, 41, 916-917.	0.9	3
137	M1718 Minimal Hepatic Encephalopathy Does Not Impair Quality of Life in Patients with Liver Cirrhosis: A Single Centre, Prospective Study. Gastroenterology, 2009, 136, A-417.	1.3	2
138	Value of Autoantibody Analysis in the Differential Diagnosis of Chronic Cholestatic Liver Disease. Clinical Gastroenterology and Hepatology, 2009, 7, 1355-1360.	4.4	42
139	Frequency of mutations related to hereditary haemochromatosis in northwestern Poland. Journal of Applied Genetics, 2008, 49, 105-107.	1.9	10
140	Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid. Liver International, 2008, 28, 997-1010.	3.9	12
141	Liver Transplantation in Primary Biliary Cirrhosis. Clinics in Liver Disease, 2008, 12, 461-472.	2.1	30
142	Biliary Tract Complications after Liver Transplantation: A Review. Digestive Surgery, 2008, 25, 245-257.	1.2	171
143	Coordinate Regulation of Hepatic Bile Acid Oxidation and Conjugation by Nuclear Receptors. Molecular Pharmaceutics, 2006, 3, 212-222.	4.6	51
144	Oxidative stress induces actin-cytoskeletal and tight-junctional alterations in hepatocytes by a Ca2+-dependent, PKC-mediated mechanism: Protective effect of PKA. Free Radical Biology and Medicine, 2006, 40, 2005-2017.	2.9	52

#	Article	IF	CITATIONS
145	Oxidative Stress Induces Internalization of the Bile Salt Export Pump, Bsep, and Bile Salt Secretory Failure in Isolated Rat Hepatocyte Couplets: A Role for Protein Kinase C and Prevention by Protein Kinase A. Toxicological Sciences, 2006, 91, 150-158.	3.1	69
146	Diffuse Skin Reaction in Patient with Hepatitis B, Treated with Two Different Formulations of Pegylated Interferon. Canadian Journal of Gastroenterology & Hepatology, 2005, 19, 677-678.	1.7	12
147	Primary Biliary Cirrhosis in A Patient with Turner Syndrome. Canadian Journal of Gastroenterology & Hepatology, 2005, 19, 631-633.	1.7	16
148	Can Turner syndrome teach us about the pathogenesis of chronic cholestasis?. Hepatology, 2004, 40, 1226-1228.	7.3	19
149	Obstetric cholestasis with elevated gamma glutamyl transpeptidase: Incidence, presentation and treatment. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1283-1286.	2.8	37
150	Pathobiology and experimental therapeutics in hepatocellular cholestasis: lessons from the hepatocyte couplet model. Clinical Science, 2002, 102, 603-614.	4.3	10
151	Pathobiology and experimental therapeutics in hepatocellular cholestasis: lessons from the hepatocyte couplet model. Clinical Science, 2002, 102, 603.	4.3	10
152	Obstetric cholestasis. BMJ: British Medical Journal, 2002, 324, 123-124.	2.3	42
153	Transplantation for cystic fibrosis: Outcome following early liver transplantation. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 208-213.	2.8	99
154	Effect of tauroursodeoxycholate and S-adenosyl-l-methionine on $17\hat{l}^2$ -estradiol glucuronide-induced cholestasis. Journal of Hepatology, 2001, 34, 184-191.	3.7	15
155	Visualization of the transport of primary and secondary bile acids across liver tissue in rats: in vivo study with fluorescent bile acids. Journal of Hepatology, 2001, 34, 4-10.	3.7	8
156	Wilson's disease with superimposed autoimmune features: Report of two cases and review. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 570-574.	2.8	70
157	Plasma elimination of cholyl-lysyl-fluorescein (CLF): a pilot study in patients with liver cirrhosis. Liver International, 2000, 20, 330-334.	3.9	14
158	Control by signaling modulators of the sorting of canalicular transporters in rat hepatocyte couplets: Role of the cytoskeleton. Hepatology, 2000, 32, 1342-1356.	7.3	55
159	INCREASED INCIDENCE OF CHRONIC REJECTION IN ADULT PATIENTS TRANSPLANTED FOR AUTOIMMUNE HEPATITIS: ASSESSMENT OF RISK FACTORS1. Transplantation, 2000, 70, 477-480.	1.0	56
160	Factors associated with progression of the disease before transplantation in patients with autoimmune hepatitis. Liver International, 1999, 19, 50-54.	3.9	17
161	Tauroursodeoxycholate and S-adenosyl-L-methionine exert an additive ameliorating effect on taurolithocholate-induced cholestasis: A study in isolated rat hepatocyte couplets. Hepatology, 1999, 29, 471-476.	7.3	29
162	Different pathways of canalicular secretion of sulfated and non-sulfated fluorescent bile acids: a study in isolated hepatocyte couplets and TR â° rats. Journal of Hepatology, 1999, 31, 678-684.	3.7	31

#	Article	IF	CITATIONS
163	RECURRENCE OF AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION1,2. Transplantation, 1999, 68, 253-256.	1.0	170
164	Obstructive sleep apnoea syndrome (OSAS) as a complication of carcinoid syndrome treated successfully by hepatic artery embolization. European Journal of Gastroenterology and Hepatology, 1997, 9, 217-220.	1.6	2
165	Plasma clearance of cholyl-lysyl-fluorescein: a pilot study in humans. Journal of Hepatology, 1997, 27, 1106-1109.	3.7	7
166	Synthesis, physical and biological properties of lithocholyl-lysyl-fluorescein: a fluorescent monohydroxy bile salt analogue with cholestatic properties1Dr. C.O. Mills Jr. would like to dedicate this paper to his late father, C.O. Mills Sr. who died on 18th November 1996.1. Biochimica Et Biophysica Acta - General Subjects, 1997, 1336, 485-496.	2.4	10